Lipid nanoparticles – Metvan: revealing a novel way to deliver a vanadium compound to bone cancer cells

CACICEDO, M. L.; RUIZ, M. C.; SCIOLI-MONTOTO, S.; RUIZ, M. E.; FERNÁNDEZ, M. A.; TORRES-SANCHEZ, R. M.; BARAN, E. J.; CASTRO, G. R.; LEÓN, I. E.

NEW JOURNAL OF CHEMISTRY

ROYAL SOC CHEMISTRY

Año: 2019

1144-0546

Cancer is one of the main causes of mortality worldwide. Common therapy schemes are always basedon chemotherapy, radiotherapy and/or surgery. Among chemotherapeutics, vanadium compounds haverecently emerged as non-platinum antitumor agents. In this sense, Metvan ([VIVO(Me)]) wasidentified as one of the most promising vanadium anticancer complexes. In this work, the Metvancompound was encapsulated into well designed and developed nanostructured lipid carriers (NLCs) withthe aim of improving its biopharmaceutical profile with regards to bioavailability, degradation, solubilityand cell up-take. A quality by design approach was followed to find the optimal nanoparticle formulationfor Metvan delivery. Results exhibited that the ideal formulation was obtained by using myristyl myristateas the lipid matrix and Pluronic F128 as the stabilizing agent with a mean nanoparticle size of 230.8 3.1 nm and a mean surface charge of 7.9 0.8 mV. The formulation showed an encapsulationefficiency of approximately 80% with a sustained drug release for more than 60 h. The kinetic releasemechanism of Metvan from the nanoparticles fitted the Korsmeyer?Peppas model, indicating the Fickiandiffusion of Metvan from the nanoparticles. On the other hand, the results showed that thenanoparticle-Metvan system is more effective to decrease cell viability on human osteosarcoma cells(MG-63) compared to the free drug, suggesting a possible different cell internalization mechanism andintracellular effect.2phen)2(SO4